NCT06087770View on ClinicalTrials.gov

Clinical Study of SM3321 With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

August 19, 2025

Study Completion Date

October 14, 2025

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

SM3321

Intravenous infusion, once a week, 28 days for a dosing cycle

Trial Locations (3)

201210

RECRUITING

Shanghai General Hospital, Shanghai

310009

NOT_YET_RECRUITING

The second affiliated hospital Zhejiang university School of Medicine, Hangzhou

510120

NOT_YET_RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Beijing StarMab Biomed Technology Ltd

INDUSTRY

NCT06087770 - Clinical Study of SM3321 With Solid Tumors | Biotech Hunter | Biotech Hunter